Gerwin Winter News Today

BRUKINSA is the only Bruton's Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA® (ibrutinib) in relapsed/refractory CLL.BRUKINSA also showed...

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLLIf approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trialsWith significantly lower rates of atrial fibrillat...

Press release content from Business Wire. The AP news staff was not involved in its creation.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and ...

 

GuruFocus Article or News written by Business Wire and the topic is about:

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace

EU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene